Fig 1: Signaling pathways involved in AURKA-stimulated p-p38 MAPK upregulation in A375 and skmel-5 cells(A) Flow cytometry analysis of apoptosis in A375 and skmel-5 cells after treatment with ALS, p38 MAPK siRNA, or p38 MAPK siRNA + ALS for 24 hours; (B) Flow cytometry analysis of autophagy in A375 and skmel-5 cells after treatment with ALS, p38 MAPK siRNA, or p38 MAPK siRNA + ALS for 24 hours; (C) Quantification of apoptotic A375 and skmel-5 cells after treatment with ALS, p38 MAPK siRNA, or p38 MAPK siRNA + ALS; (D) Quantification of autophagic A375 and skmel-5 cells after treatment with ALS, p38 MAPK siRNA, or p38 MAPK siRNA + ALS; (E) Western blot analysis of the levels of cleaved caspase-3, cleaved PARP, LC3-I, and LC3-II in A375 and skmel-5 cells after treatment with ALS, p38 MAPK siRNA, or p38 MAPK siRNA + ALS; (F) Quantification of the relative protein levels. Data are expressed as the means ± SD. All experiments were repeated at least three times. (*p < 0.05, **p < 0.01, ***p < 0.001).
Fig 2: AURKA-stimulated upregulation of p-p38 MAPK levels in A375 and skmel-5 cells(A) Western blot analysis of p38 MAPK signaling pathway components in A375 and skmel-5 cells; (B) Quantification of the relative protein levels; (C) Immunofluorescence analysis of p-p38 MAPK levels in A375 and skmel-5 cells; (D) Quantification of the relative immunofluorescence intensities; (E) Images of tumor cell morphology in the different treatment groups; (F) Tumor weights in the different treatment groups; (G) Tumor growth curves. Data are expressed as the means ± SD. All experiments were repeated at least three times. (*p < 0.05, **p < 0.01, ***p < 0.001).
Supplier Page from Cell Signaling Technology for SignalSilence ® Aurora A/AIK siRNA I